References in periodicals archive ?
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation (SPORTIF III): randomised controlled trial.
The direct thrombin inhibitors (DTIs) lepirudin and argatroban are used to achieve effective anticoagulation in patients with heparin-induced thrombocytopenia with or without thrombosis (type II) (8-10).
Direct Thrombin Inhibitors (DTIs): Argatroban, Lepirudin, Bivalirudin
The RE-MODEL trial is part of RE-VOLUTION (TM), a multi-centre, randomised global trial programme initiated by Boehringer Ingelheim in thromboembolic diseases investigating the novel oral direct thrombin inhibitor dabigatran etexilate.
Further studies investigating dabigatran etexilate The RE-VOLUTION(TM) trial program is designed to investigate the novel oral direct thrombin inhibitor dabigatran etexilate as a potential treatment, prevention and prophylaxis for several thromboembolic disease conditions.
This growth will be further supported by the high incidence rate of the disease, increased uptake of factor Xa inhibitor and direct thrombin inhibitor, and the launch of late-stage me-too candidates with improved efficacy and safety.
The trials under the umbrella name RE-VOLUTION(TM) will involve in total more than 27,000 patients worldwide and investigate a novel oral direct thrombin inhibitor, dabigatran etexilate (RENDIX(TM)) from Boehringer Ingelheim`s Research and Development for the prevention and treatment of thromboembolic disease.
A number of trials of ximelagatran--one of at least five direct thrombin inhibitors in various stages of development--have recently been reported.
Other antithrombotic agents being evaluated include oral heparins; other direct thrombin inhibitors like lepirudin, bivalirudin, and argatroban; defibrinating agents such as ancrod; anti-inflammatory agents such as P-selectin inhibitors; Factor VIIa inhibitors; tissue factor pathway inhibitor; and activated protein C.
Yet even if the drug's safety and efficacy were identical to that of warfarin, the investigational direct thrombin inhibitor would still be a big hit because it is so much easier to use.
The Company's second compound in development, NU172, is a direct thrombin inhibitor which has completed Phase 1b development for use as a potential short-acting anticoagulant during medical or surgical procedures.